SG11201706501VA - AMIDE COMPOUNDS AS 5-HT<sb>4</sb> RECEPTOR AGONISTS - Google Patents

AMIDE COMPOUNDS AS 5-HT<sb>4</sb> RECEPTOR AGONISTS

Info

Publication number
SG11201706501VA
SG11201706501VA SG11201706501VA SG11201706501VA SG11201706501VA SG 11201706501V A SG11201706501V A SG 11201706501VA SG 11201706501V A SG11201706501V A SG 11201706501VA SG 11201706501V A SG11201706501V A SG 11201706501VA SG 11201706501V A SG11201706501V A SG 11201706501VA
Authority
SG
Singapore
Prior art keywords
receptor agonists
amide compounds
amide
compounds
agonists
Prior art date
Application number
SG11201706501VA
Other languages
English (en)
Inventor
Ramakrishna Nirogi
Anil Karbhari Shinde
Abdul Rasheed Mohammed
Sangram Keshari Saraf
Narsimha Bogaraju
Ramkumar Subramanian
Pradeep Jayarajan
Gopinadh Bhyrapuneni
Venkateswarlu Jasti
Original Assignee
Suven Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suven Life Sciences Ltd filed Critical Suven Life Sciences Ltd
Publication of SG11201706501VA publication Critical patent/SG11201706501VA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
SG11201706501VA 2015-02-13 2016-01-07 AMIDE COMPOUNDS AS 5-HT<sb>4</sb> RECEPTOR AGONISTS SG11201706501VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN709CH2015 2015-02-13
PCT/IN2016/000008 WO2016128990A1 (fr) 2015-02-13 2016-01-07 Composés d'amide en tant qu'agonistes du récepteur de 5-ht4

Publications (1)

Publication Number Publication Date
SG11201706501VA true SG11201706501VA (en) 2017-09-28

Family

ID=55588327

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201706501VA SG11201706501VA (en) 2015-02-13 2016-01-07 AMIDE COMPOUNDS AS 5-HT<sb>4</sb> RECEPTOR AGONISTS

Country Status (29)

Country Link
US (1) US9957257B2 (fr)
EP (1) EP3265459B1 (fr)
JP (1) JP6487564B2 (fr)
KR (1) KR101966576B1 (fr)
CN (1) CN107406434B (fr)
AU (1) AU2016217461B2 (fr)
BR (1) BR112017017275A2 (fr)
CA (1) CA2975973C (fr)
CY (1) CY1121898T1 (fr)
DK (1) DK3265459T3 (fr)
EA (1) EA034618B1 (fr)
ES (1) ES2734734T3 (fr)
HR (1) HRP20191179T1 (fr)
HU (1) HUE045667T2 (fr)
IL (1) IL253848B (fr)
LT (1) LT3265459T (fr)
MA (1) MA41633B1 (fr)
MD (1) MD3265459T2 (fr)
ME (1) ME03430B (fr)
MX (1) MX368214B (fr)
NZ (1) NZ734400A (fr)
PL (1) PL3265459T3 (fr)
PT (1) PT3265459T (fr)
RS (1) RS59066B1 (fr)
SG (1) SG11201706501VA (fr)
SI (1) SI3265459T1 (fr)
TR (1) TR201909997T4 (fr)
WO (1) WO2016128990A1 (fr)
ZA (1) ZA201705292B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106831541B (zh) 2011-11-18 2019-09-06 赫普泰雅治疗有限公司 毒蕈碱性m1受体激动剂
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
GB201709652D0 (en) * 2017-06-16 2017-08-02 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds
CN110818661B (zh) * 2019-12-02 2021-08-06 上海再启生物技术有限公司 5-ht4受体激动剂的关键中间体4-氨基-5-卤苯并呋喃-7-羧酸的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4704353B2 (ja) 2003-11-24 2011-06-15 ファイザー株式会社 5−ht4受容体アゴニスト活性を有するキノリンカルボン酸化合物
WO2005092882A1 (fr) * 2004-03-01 2005-10-06 Pfizer Japan, Inc. Derives de 4-amino-5-halogeno-benzamide utiles comme agonistes du recepteur 5-ht4 dans le traitement des troubles gastro-intestinaux, du systeme nerveux central, neurologiques et cardio-vasculaires
ES2523459T3 (es) 2005-02-25 2014-11-26 Raqualia Pharma Inc Derivados de benzisoxazol
EP1910340B1 (fr) 2005-07-22 2009-11-18 Pfizer, Inc. Derives d'indazolecarboxamides en tant qu'agonistes des recepteurs 5ht4
WO2007048643A1 (fr) * 2005-10-28 2007-05-03 Glaxo Group Limited Nouveau composé
GB0525661D0 (en) * 2005-12-16 2006-01-25 Glaxo Group Ltd Novel compounds
GB0603550D0 (en) * 2006-02-22 2006-04-05 Glaxo Group Ltd Novel compounds
EP2533780B1 (fr) * 2010-02-12 2017-08-23 AskAt Inc. Agonistes du récepteur 5-ht4 pour le traitement de la démence
IN2012DN06631A (fr) 2010-02-16 2015-10-23 Pfizer
BR112014001083B8 (pt) * 2011-09-19 2022-06-14 Suven Life Sciences Ltd Composto, processo para a preparação de um composto, composição farmacêutica, uso da composiçâo farmacêutica e uso do composto
MX364929B (es) * 2013-03-20 2019-05-14 Suven Life Sciences Ltd Derivados de la 5-amino-quinolina-8-carboxamida como agonistas del receptor 5-ht4.
EA029951B1 (ru) 2013-12-16 2018-06-29 Сувен Лайф Сайенсиз Лимитед Соединения индазола в качестве агонистов 5-ht-рецептора

Also Published As

Publication number Publication date
CA2975973C (fr) 2019-07-16
EP3265459B1 (fr) 2019-05-15
WO2016128990A1 (fr) 2016-08-18
DK3265459T3 (da) 2019-07-15
MD3265459T2 (ro) 2019-09-30
IL253848A0 (en) 2017-09-28
AU2016217461B2 (en) 2018-07-05
MX368214B (es) 2019-09-24
KR101966576B1 (ko) 2019-04-05
HRP20191179T1 (hr) 2019-10-04
PL3265459T3 (pl) 2019-09-30
HUE045667T2 (hu) 2020-01-28
IL253848B (en) 2018-01-31
US9957257B2 (en) 2018-05-01
SI3265459T1 (sl) 2019-09-30
RS59066B1 (sr) 2019-09-30
ME03430B (fr) 2020-01-20
ES2734734T3 (es) 2019-12-11
PT3265459T (pt) 2019-07-17
TR201909997T4 (tr) 2019-07-22
ZA201705292B (en) 2019-06-26
MA41633A (fr) 2019-05-15
CN107406434B (zh) 2020-09-11
MX2017010348A (es) 2018-06-07
NZ734400A (en) 2018-03-23
CY1121898T1 (el) 2020-10-14
CN107406434A (zh) 2017-11-28
CA2975973A1 (fr) 2016-08-18
JP2018509396A (ja) 2018-04-05
MA41633B1 (fr) 2019-07-31
KR20170117167A (ko) 2017-10-20
EA034618B1 (ru) 2020-02-27
EP3265459A1 (fr) 2018-01-10
LT3265459T (lt) 2019-08-26
US20180051011A1 (en) 2018-02-22
EA201791829A1 (ru) 2018-05-31
AU2016217461A1 (en) 2017-09-14
JP6487564B2 (ja) 2019-03-20
BR112017017275A2 (pt) 2018-04-17

Similar Documents

Publication Publication Date Title
IL248347B (en) Compounds and preparations as agonists of toll-like receptor 7
IL248311B (en) Compounds and preparations as agonists of toll-like receptor 7
SG11201706501VA (en) AMIDE COMPOUNDS AS 5-HT&lt;sb&gt;4&lt;/sb&gt; RECEPTOR AGONISTS
HK1255163A1 (zh) 作為apj受體激動劑的雜芳基羥基嘧啶酮
IL246469B (en) Compounds for use as gpr120 agonists
HK1257166A1 (zh) 作為大麻素受體2激動劑的苯基衍生物
IL247143A0 (en) A new use of agonistic compounds for the sigma-1 receptor
SG11201604849YA (en) INDAZOLE COMPOUNDS AS 5-HT&lt;sb&gt;4&lt;/sb&gt; RECEPTOR AGONISTS
HK1251831A1 (zh) 作為選擇性5-ht(2c)受體激動劑的環丙基甲胺
ZA202000758B (en) Fluoropiperidine compounds as pure 5-ht6 receptor antagonists